Jerry S Wolinsky

List of Publications by Year
in descending order

155 papers	32,817 citations	30070 54 h-index	7745 150 g-index
166 all docs	166 docs citations	166 times ranked	19037 citing authors

#	Article	IF	Citations
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	5.3	8,001
2	Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 2001, 50, 121-127.	5.3	6,122
3	Diagnostic criteria for multiple sclerosis: 2005 revisions to the â€œMcDonald Criteriaâ€. Annals of Neurology, 2005, 58, 840-846.	5.3	4,495
4	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
5	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
6	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
7	Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2011, 365, 1293-1303.	27.0	842
8	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2014, 13, 247-256.	10.2	476
9	Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology, 2007, 61, 14-24.	5.3	394
10	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084.	13.7	379
11	Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Annals of Neurology, 1998, 43, 56-71.	5.3	310
12	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal, 2014, 20, 705-716.	3.0	295
13	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2014, 13, 977-986.	10.2	254
14	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology, 2020, 77, 1132.	9.0	245
15	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	27.0	237
16	Primary culture of capillary endothelium from rat brain. In Vitro, 1981, 17, 353-362.	1.2	226
17	Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. New England Journal of Medicine, 2019, 380, 2406-2417.	27.0	219
18	Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurology, The, 2012, 11, 467-476.	10.2	211

#	Article	IF	Citations
19	Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology, 2013, 73, 327-340.	5.3	182
20	Progressive Rubella Panencephalitis. New England Journal of Medicine, 1975, 292, 990-993.	27.0	167
21	Varicella-Zoster Virus Infections in Patients Treated With Fingolimod. JAMA Neurology, 2015, 72, 31.	9.0	142
22	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain, 2019, 142, 2787-2799.	7.6	136
23	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Multiple Sclerosis Journal, 2019, 25, 1915-1925.	3.0	122
24	Proton Magnetic Resonance Spectroscopy in Multiple Sclerosis. Neuroimaging Clinics of North America, 2009, 19, 45-58.	1.0	111
25	Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Multiple Sclerosis Journal, 2001, 7, 221-226.	3.0	108
26	Unified Approach for Multiple Sclerosis Lesion Segmentation on Brain MRI. Annals of Biomedical Engineering, 2006, 34, 142-151.	2.5	105
27	Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1122-1129.	3.0	102
28	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 998-1009.	10.2	98
29	Imaging of multiple sclerosis: Role in neurotherapeutics. NeuroRx, 2005, 2, 277-303.	6.0	92
30	Multiple sclerosis diagnostic criteria: three years later. Multiple Sclerosis Journal, 2005, 11, 5-12.	3.0	81
31	Evolving expectations around early management of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 351-367.	3.5	81
32	Five years of ocrelizumab in relapsing multiple sclerosis. Neurology, 2020, 95, e1854-e1867.	1.1	81
33	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsingâ€“Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. CNS Drugs, 2020, 34, 185-196.	5.9	80
34	Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurology, The, 2006, 5, 213-220.	10.2	79
35	Deep gray matter atrophy in multiple sclerosis: A tensor based morphometry. Journal of the Neurological Sciences, 2009, 282, 39-46.	0.6	77
36	Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1625-1632.	3.0	75

#	Article	IF	Citations
37	Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders, 2016, 5, 97-104.	2.0	75
38	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology, 2021, 97, e1546-e1559.	1.1	75
39	Segmentation and quantification of black holes in multiple sclerosis. NeuroImage, 2006, 29, 467-474.	4.2	73
40	Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Multiple Sclerosis Journal, 2003, 9, 349-355.	3.0	72
41	Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study. NeuroImage: Clinical, 2013, 2, 120-131.	2.7	72
42	Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Multiple Sclerosis Journal, 2013, 19, 1310-1319.	3.0	69
43	Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders, 2019, 30, 236-243.	2.0	69
44	Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. Radiology, 2020, 294, 398-404.	7.3	67
45	Teriflunomide slows BVL in relapsing MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e390.	6.0	65
46	A dual approach for minimizing false lesion classifications on magnetic resonance images. Magnetic Resonance in Medicine, 1997, 37, 94-102.	3.0	64
47	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64
48	Accuracy and Reproducibility in Volumetric Analysis of Multiple Sclerosis Lesions. Journal of Computer Assisted Tomography, 1993, 17, 200-205.	0.9	63
49	The diagnosis of primary progressive multiple sclerosis. Journal of the Neurological Sciences, 2003, 206, 145-152.	0.6	63
50	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology, 2019, 266, 1182-1193.	3.6	61
51	Consensus definitions for pediatric MS and other demyelinating disorders in childhood. Neurology, 2016, 87, S8-S11.	1.1	59
52	Phase-sensitive T1 inversion recovery imaging: a time-efficient interleaved technique for improved tissue contrast in neuroimaging. American Journal of Neuroradiology, 2005, 26, 1432-8.	2.4	59
53	Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study. Multiple Sclerosis Journal, 2020, 26, 1217-1226.	3.0	58
54	Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: Use of virus-containing cells in the urine to assess response to therapy. Annals of Neurology, 1977, 1, 458-462.	5.3	57

#	Article	IF	Citations
55	Multimodal Quantitative Magnetic Resonance Imaging of Thalamic Development and Aging across the Human Lifespan: Implications to Neurodegeneration in Multiple Sclerosis. Journal of Neuroscience, 2011, 31, 16826-16832.	3.6	57
56	A quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating disease. Annals of Neurology, 1985, 18, 324-328.	5.3	56
57	Diffusion-Tensor MR Imaging of Cortical Lesions in Multiple Sclerosis: Initial Findings. Radiology, 2008, 246, 880-886.	7.3	55
58	GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 370-376.	2.0	52
59	Cervical Spinal Cord Lesions in Multiple Sclerosis: T1-weighted Inversion-Recovery MR Imaging with Phase-Sensitive Reconstruction. Radiology, 2008, 246, 258-264.	7.3	50
60	Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Current Opinion in Neurology, 2002, 15, 247-251.	3.6	49
61	Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. Journal of Magnetic Resonance Imaging, 1992, 2, 263-270.	3.4	47
62	Isolated brain capillaries: A model for the study of lead encephalopathy. Annals of Neurology, 1977, 1, 235-239.	5.3	46
63	Human brain atlas-based multimodal MRI analysis of volumetry, diffusimetry, relaxometry and lesion distribution in multiple sclerosis patients and healthy adult controls: Implications for understanding the pathogenesis of multiple sclerosis and consolidation of quantitative MRI results in MS. Journal of the Neurological Sciences, 2012, 313, 99-109.	0.6	45
64	Ingested IFN-Î± has biological effects in humans with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 1-7.	3.0	44
65	The production of a membrane by purified oligodendroglia maintained in culture. Experimental Cell Research, 1982, 137, 203-215.	2.6	43
66	Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-?) does not improve experimental autoimmune encephalomyelitis. Annals of Neurology, 2000, 47, 127-131.	5.3	42
67	Hypoperfusion and T1-hypointense lesions in white matter in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 365-373.	3.0	42
68	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology, 2018, 84, 527-536.	5.3	42
69	Subacute measles encephalitis complicating Hodgkin's disease in an adult. Annals of Neurology, 1977, 1, 452-457.	5.3	41
70	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal, 2018, 24, 1862-1870.	3.0	41
71	Diroximel fumarate (DRF) in patients with relapsingâ€“remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis Journal, 2020, 26, 1729-1739.	3.0	41
72	THE NEUROPATHOLOGY OF PROGRESSIVE RUBELLA PANENCEPHALITIS OF LATE ONSET. Brain, 1976, 99, 81-90.	7.6	40

#	Article	IF	Citations
73	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology, 2010, 68, 409-411.	5.3	40
74	Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. Journal of the Neurological Sciences, 2009, 286, 92-98.	0.6	39
75	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology, 2019, 93, e1778-e1786.	1.1	37
76	Multiâ€modal quantitative MRI investigation of brain tissue neurodegeneration in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2012, 35, 1300-1311.	3.4	36
77	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of Neurology, 2013, 260, 2472-2480.	3.6	35
78	Segmentation of gadolinium-enhanced lesions on MRI in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2007, 25, 932-937.	3.4	34
79	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life â€“ A post hoc analysis of the TEMSO and TOWER studies. Multiple Sclerosis and Related Disorders, 2016, 7, 33-40.	2.0	32
80	Short TE hydrogen-1 spectroscopic MR imaging of normal human brain: Reproducibility studies. Journal of Magnetic Resonance Imaging, 1994, 4, 545-551.	3.4	31
81	Glatiramer acetate for the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy, 2004, 5, 875-891.	1.8	31
82	Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data. Multiple Sclerosis and Related Disorders, 2015, 4, 124-136.	2.0	31
83	Deepâ€Learningâ€Based Neural Tissue Segmentation of MRI in Multiple Sclerosis: Effect of Training Set Size. Journal of Magnetic Resonance Imaging, 2020, 51, 1487-1496.	3.4	31
84	Electron probe microanalysis of isolated brain capillaries poisoned with lead. Brain Research, 1980, 189, 369-376.	2.2	30
85	Multi-task functional MRI in multiple sclerosis patients without clinical disability. NeuroImage, 2012, 59, 573-581.	4.2	30
86	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	1.9	26
87	Chronic cerebrospinal venous insufficiency. Annals of Neurology, 2013, 73, 721-728.	5.3	24
88	Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. American Journal of Neuroradiology, 2003, 24, 75-81.	2.4	24
89	Risk evaluation and monitoring in multiple sclerosis therapeutics. Multiple Sclerosis Journal, 2014, 20, 1306-1311.	3.0	23
90	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology, 2014, 261, 1781-1788.	3.6	23

#	Article	IF	Citations
91	INGESTED INTERFERON ALPHA INDUCES Mx mRNA. Cytokine, 1999, 11, 492-499.	3.2	22
92	Mrâ€derived cerebral spinal fluid hydrodynamics as a marker and a risk factor for intracranial hypertension in astronauts exposed to microgravity. Journal of Magnetic Resonance Imaging, 2015, 42, 1560-1571.	3.4	20
93	EDSS variability before randomization may limit treatment discovery in primary progressive MS. Multiple Sclerosis Journal, 2013, 19, 775-781.	3.0	19
94	Limbic Pathway Correlates of Cognitive Impairment in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 37-42.	2.0	19
95	Are multi-contrast magnetic resonance images necessary for segmenting multiple sclerosis brains? A large cohort study based on deep learning. Magnetic Resonance Imaging, 2020, 65, 8-14.	1.8	19
96	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Neurology, 2021, 97, e1560-e1570.	1.1	19
97	EXPERIMENTAL PANENCEPHALITIS INDUCED IN SUCKLING MICE BY PARAINFLUENZA I (6/94) VIRUS. Journal of Neuropathology and Experimental Neurology, 1976, 35, 271-286.	1.7	18
98	EXPERIMENTAL PANENCEPHALITIS INDUCED IN SUCKLING MICE BY PARAINFLUENZA TYPE 1 (6/94) VIRUS. Journal of Neuropathology and Experimental Neurology, 1976, 35, 259-270.	1.7	17
99	The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods. , 1997, 51, 280-283.		17
100	Interferon-beta antibodies: implications for the treatment of MS. Lancet Neurology, The, 2003, 2, 528.	10.2	17
101	Comparative utility of disability progression measures in PPMS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e358.	6.0	17
102	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the <scp>INFORMS</scp> study. Annals of Clinical and Translational Neurology, 2018, 5, 346-356.	3.7	17
103	Is 3D MPRAGE better than the combination DIR/PSIR for cortical lesion detection at 3T MRI?. Multiple Sclerosis and Related Disorders, 2014, 3, 253-257.	2.0	16
104	Effect of inâ€painting on cortical thickness measurements in multiple sclerosis: A large cohort study. Human Brain Mapping, 2015, 36, 3749-3760.	3.6	15
105	Optimal combination of FLAIR and T2â€weighted MRI for improved lesion contrast in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2016, 44, 1293-1300.	3.4	15
106	Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. Multiple Sclerosis and Related Disorders, 2017, 18, 95-102.	2.0	15
107	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Multiple Sclerosis Journal, 2018, 24, 535-539.	3.0	15
108	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension studyâ˜…â˜…. Multiple Sclerosis and Related Disorders, 2019, 33, 131-138.	2.0	15

#	Article	IF	Citations
109	Optimizing immunomodulatory therapy for MS patients: an integrated management model. Journal of the Neurological Sciences, 2002, 201, 89-90.	0.6	14
110	Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. Multiple Sclerosis and Related Disorders, 2020, 46, 102438.	2.0	14
111	Assessment of Racial/Ethnic Disparities in Volumetric MRI Correlates of Clinical Disability in Multiple Sclerosis: A Preliminary Study. Journal of Neuroimaging, 2021, 31, 115-123.	2.0	14
112	An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis. International Journal of MS Care, 2020, 22, 226-232.	1.0	14
113	EXPERIMENTAL PANENCEPHALITIS INDUCED IN SUCKLING MICE BY PARAINFLUENZA TYPE 1 (6/94) VIRUS. Journal of Neuropathology and Experimental Neurology, 1976, 35, 247-258.	1.7	13
114	Comparison of human cytomegalovirus growth in MRC-5 human fibroblasts, brain, and choroid plexus cells in vitro. Journal of Medical Virology, 1981, 8, 245-256.	5.0	13
115	Serial immune evaluation of cyclosporine- and placebo-treated multiple sclerosis patients. Journal of Neuroimmunology, 1988, 18, 325-331.	2.3	13
116	Decreased CD3-mediated interferon-? production in relapsing-remitting multiple sclerosis. Annals of Neurology, 1995, 37, 546-549.	5.3	13
117	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple Sclerosis Journal, 2022, 28, 790-800.	3.0	13
118	Lateral ventricular cerebrospinal fluid diffusivity as a potential neuroimaging marker of brain temperature in multiple sclerosis: a hypothesis and implications. Magnetic Resonance Imaging, 2015, 33, 262-269.	1.8	12
119	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. Neurology, 2021, 97, e1334-e1342.	1.1	12
120	Encephalitis after inhalation of measles virus: A pathogenetic study in hamsters. Annals of Neurology, 1981, 9, 21-27.	5.3	11
121	Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis. Journal of Neuroimmunology, 2019, 326, 45-48.	2.3	11
122	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. European Journal of Neurology, 2022, 29, 1082-1090.	3.3	11
123	Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment. Multiple Sclerosis Journal, 2013, 19, 1499-1507.	3.0	10
124	Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal, 2022, 28, 1927-1936.	3.0	10
125	Risk of requiring a walking aid after 6.5Âyears of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. European Journal of Neurology, 2022, 29, 1238-1242.	3.3	9
126	Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 836-847.	3.0	8

#	Article	IF	Citations
127	Rational therapy for relapsing multiple sclerosis. Lancet Neurology, The, 2003, 2, 271-272.	10.2	7
128	Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note. Multiple Sclerosis Journal, 2017, 23, 982-987.	3.0	7
129	Lymphocyte counts and infection rates. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	7
130	Contrast enhanced MR venography with gadofosveset trisodium: Evaluation of the intracranial and extracranial venous system. Journal of Magnetic Resonance Imaging, 2014, 40, 630-640.	3.4	6
131	Recruitment of participants to a multiple sclerosis trial: The CombiRx experience. Clinical Trials, 2014, 11, 159-166.	1.6	6
132	Interleaved susceptibilityâ€weighted and FLAIR MRI for imaging lesionâ€penetrating veins in multiple sclerosis. Magnetic Resonance in Medicine, 2018, 80, 1132-1137.	3.0	6
133	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
134	An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732091193.	1.0	6
135	061â€…Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.2-A25.	1.9	5
136	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	3.0	5
137	Use of magnetic resonance imaging in the diagnosis of multiple sclerosis. Policy statement of the National Multiple Sclerosis Society, New York. Magnetic Resonance in Medicine, 1986, 3, 821-822.	3.0	4
138	Effect of cyclosporine on rubella virus-specific immune responses in chronic progressive multiple sclerosis. Journal of Neuroimmunology, 1989, 22, 143-148.	2.3	4
139	Multimodal MRI Segmentation of Brain Tissue and T2-Hyperintense White Matter Lesions in Multiple Sclerosis using Deep Convolutional Neural Networks and a Large Multi-center Image Database. , 2018, , .		4
140	Report of the Consensus Panel on the New International Panel Guidelines for Diagnosis of MS. International Journal of MS Care, 2002, 4, 170-173.	1.0	4
141	033â€…Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A14.1-A14.	1.9	3
142	Antibody Response to Rubella Virus Antigen and Structural Proteins in Retinitis Pigmentosa. Journal of Infectious Diseases, 1992, 166, 528-530.	4.0	2
143	A comparative study of correlation coefficients in spatially MRSI-observed neurochemicals from multiple sclerosis patients. Journal of Applied Statistics, 2003, 30, 1221-1229.	1.3	2
144	Patientâ€specific 3D FLAIR for enhanced visualization of brain white matter lesions in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2017, 46, 557-564.	3.4	2

#	Article	IF	Citations
145	068â€…Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A28.1-A28.	1.9	2
146	The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsingâ€“Remitting Multiple sclerosis: A CombiRx Secondary Analysis. Journal of Central Nervous System Disease, 2021, 13, 117957352110421.	1.9	2
147	Patient selection for trials. Multiple Sclerosis Journal, 2017, 23, 1636-1641.	3.0	1
148	Preliminary results of the opera i and opera ii open-label extension study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.90-e1.	1.9	1
149	Characterizing the time course of cerebrovascular reactivity in multiple sclerosis. Journal of Neuroimaging, 2022, , .	2.0	1
150	Early firstâ€line treatment response and subsequent disability worsening in relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2022, 29, 1106-1116.	3.3	1
151	Early versus delayed treatment with glatiramer acetate: Analysis of up to 27â€‰years of continuous follow-up in a US open-label extension study. Multiple Sclerosis Journal, 2022, 28, 1729-1743.	3.0	1
152	Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.85-e1.	1.9	0
153	PO128â€…Infusion-related reactions with ocrelizumab in rms and ppms. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.1-A46.	1.9	0
154	Imaging of multiple sclerosis: Role in neurotherapeutics. Neurotherapeutics, 2005, 2, 277-303.	4.4	0
155	031â€… Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A23.1-A23.	1.9	0